688298 东方生物
2026/03 - 三个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)-1.579-9.077-7.514-5.09827.533
总资产报酬率 ROA (%)-1.338-7.531-6.191-4.03621.013
投入资产回报率 ROIC (%)-1.482-8.457-6.908-4.61325.748

边际利润分析
销售毛利率 (%)42.89440.79531.74143.01150.793
营业利润率 (%)-36.219-61.458-69.914-46.80028.835
息税前利润/营业总收入 (%)-29.381-68.250-96.948-82.88821.299
净利润/营业总收入 (%)-38.515-63.059-68.705-50.99923.922

收益指标分析
经营活动净收益/利润总额(%)97.00167.59472.19845.059149.748
价值变动净收益/利润总额(%)-10.920-1.214-6.908-8.1700.311
营业外收支净额/利润总额(%)0.0100.2141.1075.045-2.326

偿债能力分析
流动比率 (X)3.7873.9143.3055.4303.839
速动比率 (X)3.4213.5423.0495.1113.650
资产负债率 (%)13.17514.75416.09916.07622.242
带息债务/全部投入资本 (%)5.3155.0106.1977.7529.840
股东权益/带息债务 (%)1,763.1271,876.3251,491.2711,180.349910.406
股东权益/负债合计 (%)648.995568.963509.926514.172342.869
利息保障倍数 (X)-4.29510.2483.6932.467-3.096

营运能力分析
应收账款周转天数 (天)68.63883.81694.411113.14130.666
存货周转天数 (天)185.659198.589208.859299.88137.652